Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

医学 软膜 卡铂 肿瘤科 安慰剂 内科学 BRCA突变 乳腺癌 化疗 癌症 紫杉醇 替代医学 遗传学 聚ADP核糖聚合酶 顺铂 生物 病理 基因 聚合酶
作者
Veronique C Dieras,Hyo Sook Han,Bella Kaufman,Hans P. M. W. Wildiers,Michael Leonard Friedlander,Jean-Pierre Ayoub,Shannon L. Puhalla,Igor Bondarenko,Mario Campone,Erik Hugger Jakobsen,Mathilde Jalving,Cristina Marinela Oprean,Markéta Palácová,Yeon Hee Park,Yaroslav V. Shparyk,Eduardo Yáñez,Nikhil Khandelwal,Madan G. Kundu,Matthew W. Dudley,Christine K. Ratajczak
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (10): 1269-1282 被引量:352
标识
DOI:10.1016/s1470-2045(20)30447-2
摘要

Background BRCA1 or BRCA2 -mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage. In this trial, we compared veliparib versus placebo in combination with carboplatin and paclitaxel, and continued as monotherapy if carboplatin and paclitaxel were discontinued before progression, in patients with HER2-negative advanced breast cancer and a germline BRCA1 or BRCA2 mutation. Methods BROCADE3 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 147 hospitals in 36 countries. Eligible patients (aged ≥18 years) had deleterious germline BRCA1 or BRCA2 mutation-associated, histologically or cytologically confirmed advanced HER2-negative breast cancer, an Eastern Cooperative Oncology Group performance status of 0–2, and had received up to two previous lines of chemotherapy for metastatic disease. Patients were randomly assigned (2:1) by interactive response technology by means of permuted blocks within strata (block size of 3 or 6) to carboplatin (area under the concentration curve 6 mg/mL per min intravenously) on day 1 and paclitaxel (80 mg/m 2 intravenously) on days 1, 8, and 15 of 21-day cycles combined with either veliparib (120 mg orally twice daily, on days −2 to 5) or matching placebo. If patients discontinued carboplatin and paclitaxel before progression, they could continue veliparib or placebo at an intensified dose (300 mg twice daily continuously, escalating to 400 mg twice daily if tolerated) until disease progression. Patients in the control group could receive open-label veliparib monotherapy after disease progression. Randomisation was stratified by previous platinum use, history of CNS metastases, and oestrogen and progesterone receptor status. The primary endpoint was investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1. Efficacy analyses were done by intention to treat, which included all randomly assigned patients with a centrally confirmed BRCA mutation, and safety analyses included all patients who received at least one dose of velilparib or placebo. This study is ongoing and is registered with ClinicalTrials.gov, NCT02163694. Findings Between July 30, 2014, and Jan 17, 2018, 2202 patients were screened, of whom 513 eligible patients were enrolled and randomly assigned. In the intention-to-treat population (n=509), 337 patients were assigned to receive veliparib plus carboplatin–paclitaxel (veliparib group) and 172 were assigned to receive placebo plus carboplatin–paclitaxel (control group). Median follow-up at data cutoff (April 5, 2019) was 35·7 months (IQR 24·9–43·6) in the veliparib group and 35·5 months (23·1–45·9) in the control group. Median progression-free survival was 14·5 months (95% CI 12·5–17·7) in the veliparib group versus 12·6 months (10·6–14·4) in the control group (hazard ratio 0·71 [95% CI 0·57–0·88], p=0·0016). The most common grade 3 or worse adverse events were neutropenia (272 [81%] of 336 patients in the veliparib group vs 143 [84%] of 171 patients in the control group), anaemia (142 [42%] vs 68 [40%]), and thrombocytopenia (134 [40%] vs 48 [28%]). Serious adverse events occurred in 115 (34%) patients in the veliparib group versus 49 (29%) patients in the control group. There were no study drug-related deaths. Interpretation The addition of veliparib to a highly active platinum doublet, with continuation as monotherapy if the doublet were discontinued, resulted in significant and durable improvement in progression-free survival in patients with germline BRCA mutation-associated advanced breast cancer. These data indicate the utility of combining platinum and PARP inhibitors in this patient population. Funding AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
9202211125完成签到,获得积分10
1秒前
1秒前
1秒前
123完成签到,获得积分10
1秒前
海绵研研完成签到 ,获得积分10
1秒前
Inter09完成签到,获得积分10
1秒前
arniu2008发布了新的文献求助10
1秒前
乖乖羊完成签到,获得积分10
2秒前
binbin完成签到,获得积分10
3秒前
流觞俊秀完成签到 ,获得积分10
3秒前
负责的紫安完成签到 ,获得积分10
3秒前
3秒前
博士搏斗完成签到 ,获得积分10
4秒前
海燕完成签到 ,获得积分10
4秒前
马格发布了新的文献求助10
5秒前
5秒前
澪617完成签到,获得积分10
5秒前
无极微光的应助被叫我第一名采纳,获得20
5秒前
Xiaoyan完成签到,获得积分10
6秒前
小圆子完成签到,获得积分10
6秒前
alei1203完成签到,获得积分10
6秒前
6秒前
一氧化二氢完成签到,获得积分10
6秒前
帆子完成签到 ,获得积分10
7秒前
zhanga发布了新的文献求助10
7秒前
CodeCraft的应助被独一无二的鱼采纳,获得10
7秒前
鹧鸪完成签到 ,获得积分10
7秒前
孙新雨完成签到,获得积分10
8秒前
LINLIN发布了新的文献求助10
8秒前
zmang完成签到 ,获得积分10
8秒前
arniu2008发布了新的文献求助10
8秒前
芯止谭轩完成签到,获得积分10
8秒前
英俊的铭的应助被zhanga采纳,获得10
8秒前
老头完成签到 ,获得积分10
8秒前
9秒前
。。完成签到,获得积分10
9秒前
wqx完成签到,获得积分10
9秒前
troyqiujing完成签到,获得积分0
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173580
求助须知:如何正确求助?哪些是违规求助? 9565737
关于积分的说明 21782083
捐赠科研通 7767775
什么是DOI,文献DOI怎么找? 3431604
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476870